X

Granules India Ltd Q2FY25; 5% fall in Profits

Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.

Financial Results:

Granules India Ltd reported Revenues for Q2FY25 of ₹967.00 Crores down from ₹1,189.00 Crore year on year, a fall of 18.67%.

Total Expenses for Q2FY25 of ₹842.00 Crores down from ₹1,056.00 Crores year on year, a fall of 20.27%.

Consolidated Net Profit of ₹97.00 Crores down 4.9% from ₹102.00 Crores in the same quarter of the previous year.

The Earnings per Share is ₹4.01, down 4.75% from ₹4.21 in the same quarter of the previous year.

Related Post